UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 20, 2023

MATINAS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-38022 (Commission File Number) 46-3011414 (IRS Employer ID Number)

07921 (Zip Code)

Registrant's telephone number, including area code: (908) 484-8805

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

1545 Route 206 South, Suite 302 Bedminster, New Jersey

(Address of principal executive offices)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered		
Common Stock	MTNB	NYSE American		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Matinas BioPharma Holdings, Inc. (the "Company") updated its corporate presentation (the "Corporate Presentation") which it intends to use at various conferences and investor meetings. The Corporate Presentation is attached hereto as Exhibit 99 and incorporated herein by reference.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation dated September 20, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MATINAS BIOPHARMA HOLDINGS, INC.

Dated: September 20, 2023	By:	/s/ Jerome D. Jabbour
	Name:	Jerome D. Jabbour
	Title:	Chief Executive Officer
	,	
)-	

-

MATINAS

BIOPHARMA

Corporate Presentation


September/October 2023

www.matinasbiopharma.com NYSE American: MTNB

Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.


Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value



Internal and External Pipeline



Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform



Delivery of small molecules and small oligonucleotides

Successful delivery of small molecules, proteins, small oligos (siRNA, ASOs), and vaccines

Extra-hepatic targeting

- Selective uptake driven by phosphatidylserine enables delivery in infection, inflammation, oncology
- Validated Blood-Brain-Barrier penetration (MAT2203)

Oral delivery

 Unique structure protects cargo in GI tract, avoids first-pass hepatic metabolism


Safe & stable

- Deliver high-target tissue concentrations of drug with low plasma levels and no absorption by non-target tissues
- No evidence of immunogenicity or cytotoxicity

COPYRIGHT MATINAS BIOPHARMA - 2023

BIOPHARMA

Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery




LNCs – Differentiated from Liposomes and LNPs

	Liposome	LNP	LNC
Structure	 Aqueous interior surrounded by bilayer Drug can be encapsulated in aqueous core or bilayer 	 Ionizable lipid complexing with mRNA Non-aqueous interior 	 Non-aqueous bilayer Highly stable
Formulation Strengths	Enable IV administration of insoluble products	 Intracellular delivery (ASOs, siRNAs, mRNA) Improve stability, half-life 	 Efficient intracellular delivery Large and small molecules ASOs, miRNAs, siRNAs Reduced toxicity Oral delivery
Formulation Limitations	 Liposomes often "leak" causing side effects IV Administration 	 Cationic lipid toxicity not suitable for chronic use Anti-PEG allergic response Very limited shelf stability Cold-chain requirements 	 Targeted, extra-hepatic delivery to desired cells and tissues



The Growing Threat of Invasive Fungal Infections (IFIs)




MAT2203: Unlocking the Full Potential of Amphotericin B



MAT2203 is a promising potential therapeutic option for the treatment of MULTIPLE serious and life-threatening fungal infections

COPYRIGHT MATINAS BIOPHARMA - 2023

EnACT: Phase 2 Clinical Validation of Safety and Efficacy



Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal

Clinical Infectious Diseases

MAJOR ARTICLE




Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial

David R. Boulware,^{1,a,e} Mucunguzi Atukunda,^{2,a} Enock Kagimu,² Abdu K. Musubire,² Andrew Akampurira,² Lillian Tugume,² Kenneth Ssebambulidde,^{2,3} John Kasibante,² Laura Nsangi,² Timothy Mugabi,² Jane Gakuru,² Sarah Kimuda,² Derrick Kasozi,² Suzan Namombwe,² Isaac Turyasingura,² Morris K. Rutakingirwa,² Edward Mpoza,² Enos Kigozi,⁴ Conrad Muzoora,⁴ Jayne Ellis,² Caleb P. Skipper,¹ Theresa Matkovits,⁵ Peter R. Williamson,³ Darlisha A. Williams,¹ Ann Fieberg,⁶ Kathy H. Hullsiek,⁶ Mahsa Abassi,¹ Biyue Dai,⁶ and David B. Meya^{1,2}

¹Department of Medicine, University of Minnesota, Minnesota, USA; ²Infectious Diseases Institute, Makerere University, Kampala, Uganda; ³Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA; ⁴Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; ⁵Matinas Biopharma Nanotechnologies, Bedminster, New Jersey, USA; and ⁶Division of Biostatistics, School of Public Health, University of Minnesota, Minnesota, USA USA

MAT2203 Expanded Access Program – Targeted Treatment of IFIs Throughout the Body



MAT2203 Expanded Access/Compassionate Use Program

Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options

- 11 patients with no other treatment options are currently receiving or have completed treatment with MAT2203
 - Notable Healthcare Institutions: NIH, University of Michigan, Johns Hopkins, City of Hope, Nationwide Children's Hospital
- · Patients were not responding/resistant to, or unable to receive, azole therapy
- Patients were switched to treatment with IV AMB with clinical response but unable to tolerate treatment due renal toxicity
 - All patients hospitalized to monitor/manage renal safety and most received IV electrolyte supplementation
- Following oral MAT2203 initiation, patients were discharged to continue treatment at home
- · Renal toxicity reversed and renal function returned to normal
- All patients who received at least two weeks or more of treatment had positive clinical outcomes with significant success stories of full recovery in majority of patients

COPYRIGHT MATINAS BIOPHARMA - 2023

14

13

High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)

- Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients
 - ~15,000 new cases per year in the U.S. alone
 - WHO, CDC, and FDA consider IA a <u>critical priority</u> and a global public health concern
- · IDSA Guidelines recommend treatment with mold-active azoles as first-line treatment for 6-12 weeks
 - Azole use requires significant expertise to manage toxicities and significant drug-drug interactions that often limits duration of use
 - Resistance to azoles has been increasing globally
 - Recently, cases of breakthrough IA have been reported in patients receiving antifungal prophylaxis
 - Failures attributed to non-compliance, poor absorption, DDIs, or infection with a drug-resistant Aspergillus species
- Patients suffering from IA with little or no treatment options among the highest unmet medical need with approximately 3,000-5,000 cases per year (U.S. only)
 - Rare disease/orphan commercial opportunity

* Phase 3 trial dependent on securing partnership(s) or non-dilutive government funds

15

COPYRIGHT MATINAS BIOPHARMA - 2023

BIOPHARMA


MAT2203 Regulatory Strategy

- Near-term development strategy refined to narrow initial target indication: treatment of invasive aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not effectively managed with an azole)
 - Register leveraging LPAD pathway
 - Other regulatory designations protected and maintained (QIDP, ODD, Fast-Track, potential for Breakthrough Therapy)
- Restricted indication could be supported by smaller study with larger noninferiority margin (20%)
 - Regulatory precedent with Vical Program and Rezafungin approval
 - Sample size ~198 patients
 - Potential meaningful commercial opportunity in "rare disease" patient population
- FDA Type B Meeting in early Q4 to align on revised strategy and study design




To assess the efficacy and safety of MAT2203 in patients with Invasive Aspergillosis (IA) in adults who have limited or no alternative treatment options following initial intravenous treatment

Patients will be randomized 2:1 to receive either oral MAT2203 as "step down" treatment after initial treatment with IV AMB (Experimental Arm) or Standard of Care (Comparator Arm)



MAT2203 Value Proposition



LNCs Beyond MAT2203 Efficient and Safe Delivery of Small Oligos

MATINAS BIOPHARMA

LNC Experience to Date

	<i>In Vivo</i> Animal S	Studies	Human Clinical Trials	
	Animal model	Molecule Cargo	Indication	Molecule Cargo
	Cystic fibrosis mouse model	Amikacin	Mucocutaneous	Amphotericin - B
		ASO	candidiasis	
	BALB/c mouse flu model	Flu protein	Job's syndrome, NIH	
		siRNA	Vulvovaginal Candidiasis	Amphotericin - B
Infection	Mouse SARS-CoV-2 model	Remdesivir	(VVC) Phase 2	Amphotencin - B
		Homadon	HIV / cryptococcal	Amphotericin - B
	CM mouse model	Amphotericin- B	meningitis, Phase 2	Amphotonom - D
	Pneumocystis mouse model	Atovaquone		
Inflammation	Rat footpad inflammation model	NSAID		
	GvHD Mouse model	ST1959		
Oncology	Lymphocytic leukemia mouse model	ASO		

COPYRIGHT MATINAS BIOPHARMA - 2023

20


19

COPYRIGHT MATINAS BIOPHARMA - 2023


MATINAS BIOPHARMA








LNCs are Taken up by Blood Cells Human Whole Blood Flow Cytometry (3 hrs incubation with labeled LNCs)




In vitro Tumor Cell Inhibition with LNC Docetaxel Formulations




In vitro Dose-Dependent Knockdown of IL-17A in Murine T Cells

24



COPYRIGHT MATINAS BIOPHARMA - 2023

Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics



Rapid Evolution of Platform Sets Stage for Active Q4

	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023
General Platform		Proc	ess enhancements (ongoir	ng)	Oral delivery of small oligos
Infection (ID Week)			Expended Access case presentations	EnACT publication	Pipeline Presentation and <u>Potential</u> Expanded Access Late Breaker Oral Abstract (ID week October 2023)
				MAT2203 Expanded Ac	cess Program
				Small oligo LNCs	
Inflammation LNC uptake by innate immune cells ex-vivo	innate immune	LNC uptake by T- cells in vitro	Biological activity of anti-inflammatory LNC-small oligo in vitro	Biological activity of oral anti-inflammatory LNC-small oligo <i>in vivo</i>	Biological activity of <u>orally administered</u> anti-inflammator LNC-small oligos in vitro and in vivo (inflammation models
				<u>Therapeutic</u> efficacy of <u>oral</u> anti-inflammatory LNC-small oligos <i>in vivo</i> (disease model <u>s</u>)	
Oncology	I	Small molecule LNCs	Biological activity of anti-tumor LNC-small molecule <i>in vitro</i>	Formulation optimization to prepare for <i>in vivo</i> studies	Small oligo LNCs Small molecule LNCs Delivery and activity of oral LNC formulations in vivo (tumor models) (tumor models)

COPYRIGHT MATINAS BIOPHARMA - 2023

Continuingly increasing our patent suite to increase protection and exclusivity



MAT2203 potentially entitled to 12+ years of exclusivity (QIDP & Orphan status)



Global Platform IP base protection out to 2037 with 20 patents issued in last 5 years



Recent patent applications based on formulation work with small oligonucleotides

Strong IP & Regulatory Designations

COPYRIGHT MATINAS BIOPHARMA - 2023

MATINAS **OPHARM**A

Experienced Leadership Team

EXECUTIVE TEAM



Jerome D. Jabbour, J.D. Chief Executive Officer

Reliant"



James Ferguson, M.D. Chief Medical Officer

AMGEN Medicines AstraZeneca



MILLENDO Sunovion

Keith Kucinski, CPA, MBA

Chief Financial Officer

PAR barr



Chief Development Officer nps 6 NOVARTIS

dicines



Hui Liu, Ph.D., MBA Chief Technology Officer

🛟 Allergan Alcon Segirus

BOARD OF DIRECTORS



28

27

Near-Term Milestones – Setup for Strong Close to 2023 **Matinas Investment Thesis** Q4 - FDA Meeting and Feedback on MAT2203 Phase 3 Invasive Aspergillosis LPAD Study S. D Q4 – ID Week MAT2203 Pipeline Presentation and Potential Compassionate Use Late Ĵ Breaker Oral Abstract **Financial Summary** ŝ Q4 - In vivo Oral Delivery of a Functional Small Oligonucleotide (cytokine knockdown) ". N Q4 - In vivo Oral Delivery with Therapeutic Impact from Internal ASO/siRNA Program . D Q4 - Oral Delivery of an Anti-Tumor LNC Small Molecule and Small Oligonucleotide Runway into Sept. 2024 °° P Q4 - Potential MAT2203 Domestic/Regional/Global Partnership ". N Q4 - Potential New Platform Collaboration \$22.5M¹ in Cash, ŝ 2024 - Potential BARDA/ARPA-H Funding for MAT2203 and LNC Platform Cash Equivalents and Solid Value **Substantial** Marketable Securities "Foundation" ¹ as of 06/30/23 UPSIDE LNCs Facilitating ORAL Delivery MAT2203 of Small Oligonucleotides Non-Dilutive **Clinically Validated** • **Financing Options** And Phase 3-ready asset • Establishing Internal and **External Pipelines** • **Highest unmet need** MATINAS COPYRIGHT MATINAS BIOPHARMA - 2023 29 BIOPHARMA